BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Wednesday, August 14, 2024, and will host a corporate update conference call at 8:30am Eastern Time.
Wednesday, August 14th @ 8:30am ET
| Domestic: | 1-877-270-2148 |
| International: | 1-412-902-6510 |
| Webcast: | Webcast Link |
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
[email protected]
(617) 430-7576
- ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Methode Electronics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MEI - September 14, 2024
- FIVE Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Five Below, Inc. (FIVE) - September 14, 2024
- LIONS GATE ENTERTAINMENT CORP. ANNOUNCEMENT: If You Have Suffered Losses in Lions Gate Entertainment Corp. (NYSE: LGF.A, LGF.B), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - September 14, 2024
